merged_alzheimers-treatment-kisunla-donanemab.txt
<other>Answering questions based solely on the article.</other>
<question_number>1</question_number>
<answer>The risk of side effects and lack of clear correlation between plaque removal and meaningful clinical benefit</answer>
<question_number>2</question_number>
<answer>They may discourage patients from joining other trials, potentially slowing advances in other treatments</answer>
<question_number>3</question_number>
<answer>He says there is no correlation between plaque removal and clinical response in individual patients</answer>
<question_number>4</question_number>
<answer>It raises more concerns about its safety</answer>
<question_number>5</question_number>
<answer>Lilly believes patients can discontinue treatment once plaques are cleared, potentially reducing overall costs</answer>
<question_number>6</question_number>
<answer>They might make patients less likely to enroll in other trials for potentially more effective treatments</answer>
<question_number>7</question_number>
<answer>It can be discontinued once amyloid is cleared, reducing both infusions and risk</answer>
<question_number>8</question_number>
<answer>Amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>Patients with intermediate tau levels showed slower decline, indicating earlier treatment may be more effective</answer>